Day: January 26, 2022

Blog article

OSHA withdraws emergency enforcement of COVID vaccine mandate

The Occupational Safety and Health Administration is ceasing emergency enforcement of its COVID-19 mandate for large employers, but noted it’s not withdrawing it as a proposed rule.

The withdrawal, which takes effect Jan. 26, follows the U.S. Supreme Court’s 6-3 decision on Jan. 13 to stop enforcement of the rule while appeals are pending at lower courts. The court also ruled that day that the Biden administration’s COVID-19 vaccine requirement for healthcare workers could continue during appeals.

OSHA wrote in a filing Tuesday that while it’s withdrawing the emergency temporary standard as an enforceable standard, the standard is still a proposed rule. OSHA said it is prioritizing its resources to focus on finalizing a permanent COVID-19 healthcare standard.

Download Modern Healthcare’s app to stay informed when industry news breaks.

OSHA had filed the emergency temporary standard on Nov. 5, 2021. It seeks to require employers to develop, implement and enforce

Read More
Health News

Gene therapy for the treatment of Huntington’s disease

Credit: Pixabay/CC0 Public Domain

Gene therapy targeting the messenger RNA (mRNA) of the mutated huntingtin gene (HTT) can provide long-lasting therapeutic benefit in Huntington’s disease after a single administration. An adeno-associated virus (AAV) gene therapy containing a primary artificial microRNA (pri-amiRNA) targeting HTT mRNA is described in the peer-reviewed journal Human Gene Therapy.

“The challenge of treating autosomal dominant genetic brain disorders has been very daunting, and this pioneering effort by Voyager Therapeutics provides new hope for patients with one of the most tragic such diagnoses, that of Huntington’s disease,” says Editor-in-Chief of Human Gene Therapy Terence R. Flotte, MD.

Dinah Sah, Ph.D., from Voyager Therapeutics, and coauthors conducted a systematic comparison of pri-amiRNA processing of a number of AAV-pri-amiRNAs across multiple in vitro and in vivo systems, including mice and non-human primates.

The investigators selected an optimized pri-amiRNA “for an AAV that exhibits efficient and precise

Read More